155 related articles for article (PubMed ID: 4040315)
21. Renal tubular dysfunction and urinary zinc excretion in breast cancer patients treated with anthracycline-based combination chemotherapy.
Králícková P; Melichar B; Malír F; Roubal T
J Exp Clin Cancer Res; 2004 Dec; 23(4):579-84. PubMed ID: 15743027
[TBL] [Abstract][Full Text] [Related]
22. [Acute change in urinary NAG activity following CDDP administration].
Yoshida K; Takahashi T; Nakame Y; Saitoh H; Horiuchi S; Kaneoya F; Negishi T
Hinyokika Kiyo; 1986 Mar; 32(3):369-73. PubMed ID: 3728241
[TBL] [Abstract][Full Text] [Related]
23. [New treatments for urogenital toxicity of anti-neoplastic chemotherapy].
Shibuya M; Hirosawa A; Niitani H
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):950-6. PubMed ID: 2111664
[TBL] [Abstract][Full Text] [Related]
24. Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics.
Etherington C; Bosomworth M; Clifton I; Peckham DG; Conway SP
J Cyst Fibros; 2007 Jan; 6(1):67-73. PubMed ID: 16844430
[TBL] [Abstract][Full Text] [Related]
25. [Effects of urinastatin against nephrotoxicity of cisplatinum].
Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
[TBL] [Abstract][Full Text] [Related]
26. [Clinical study of nephrotoxicity following cis-diamminedichloroplatinum (II) (CDDP) combination chemotherapy assessed by 131I-OIH renogram].
Shirasaka K
Nihon Igaku Hoshasen Gakkai Zasshi; 1990 Dec; 50(12):1580-9. PubMed ID: 2089371
[TBL] [Abstract][Full Text] [Related]
27. [Acute nephrotoxicity by CDDP (on tubular damage)].
Higuchi K; Negoro Y; Suzuki M; Noguchi M; Nakanishi M; Ishihara M; Nakano M
Gan To Kagaku Ryoho; 1991 Jan; 18(1):85-9. PubMed ID: 1987905
[TBL] [Abstract][Full Text] [Related]
28. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
[TBL] [Abstract][Full Text] [Related]
29. Nephrotoxicity of cis-diamminedichloroplatinum with or without ifosfamide in cancer treatment.
Hacke M; Schmoll HJ; Alt JM; Baumann K; Stolte H
Clin Physiol Biochem; 1983; 1(1):17-26. PubMed ID: 6383688
[TBL] [Abstract][Full Text] [Related]
30. [Experimental evaluation of cisplatin analogous in urogenital cancer].
Machida T; Akasaka Y
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1386-92. PubMed ID: 2658827
[TBL] [Abstract][Full Text] [Related]
31. cis-Diamminedichloroplatinum(II) alone and in combination in the treatment of testicular and other malignancies.
Sarna G; Skinner DG; Smith RB; Zighelboim J; Goodnight JE; Feig S
Cancer Treat Rep; 1980; 64(10-11):1077-82. PubMed ID: 7193086
[TBL] [Abstract][Full Text] [Related]
32. [The effect of bismuth subnitrate on cisplatin toxicity].
Chen JT; Kurokawa Y; Nakayama K; Saito K; Sakamoto K; Fukuda K; Hirai Y; Hamada T; Fujimoto I; Yamauchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):815-22. PubMed ID: 3298471
[TBL] [Abstract][Full Text] [Related]
33. [Impact of different methods of estimating renal function on determining eligibility for cisplatin (CDDP)-based chemotherapy in patients with invasive urothelial carcinoma].
Goto T; Yoshimura K; Matsui Y; Shimizu Y; Inoue T; Okubo K; Kamba T; Nishiyama H; Ogawa O
Hinyokika Kiyo; 2011 Dec; 57(12):671-6. PubMed ID: 22240299
[TBL] [Abstract][Full Text] [Related]
34. [Effect of gamma-hydroxybutyric acid and pentoxifylline on kidney function parameters in coronary surgery interventions].
Kleinschmidt S; Bauer M; Grundmann U; Schneider A; Wagner B; Graeter T
Anaesthesiol Reanim; 1997; 22(4):102-7. PubMed ID: 9376042
[TBL] [Abstract][Full Text] [Related]
35. [Urinary NAG and gamma-GTP activities as indicators of CDDP renal toxicity: effect of fosfomycin on CDDP renal toxicity].
Yoshida K; Takahashi T; Nakame Y; Saitoh H; Horiuchi S; Kaneoya F; Negishi T
Hinyokika Kiyo; 1986 Sep; 32(9):1237-45. PubMed ID: 2880486
[TBL] [Abstract][Full Text] [Related]
36. [Changes in renal function on response to rapid administration of cisplatinum].
Mikata N; Suzuki M; Takeuchi T; Kunisawa Y; Fukutani K; Kawabe K
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):508-13. PubMed ID: 3954374
[TBL] [Abstract][Full Text] [Related]
37. [Transition of renal function after repeated intraperitoneal CDDP administration].
Arai K; Kitamura M; Iwasaki Y
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1476-8. PubMed ID: 8854784
[TBL] [Abstract][Full Text] [Related]
38. [Changes in renal function in patients with severe hepatitis and liver cancer with cirrhosis during orthotopic liver transplantation].
Li XY; Hei ZQ; Li SR; Shen N
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Jul; 19(7):386-9. PubMed ID: 17631701
[TBL] [Abstract][Full Text] [Related]
39. Serum beta 2-microglobulin after five-day administration of cisplatin.
Svobodová M; Tauer Z; Petrová-Skalková D
Neoplasma; 1988; 35(5):511-4. PubMed ID: 3063983
[TBL] [Abstract][Full Text] [Related]
40. Changes in the structure and function of the kidney of rats chronically exposed to cadmium. I. Biochemical and histopathological studies.
Brzóska MM; Kamiński M; Supernak-Bobko D; Zwierz K; Moniuszko-Jakoniuk J
Arch Toxicol; 2003 Jun; 77(6):344-52. PubMed ID: 12799774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
